Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission

Clinical Nutrition

Volumn 29, Issue 6, 2010, Pages 738-744

  Hamer, Henrike M ^a,b   Jonkers, Daisy M A E ^a,b   Vanhoutvin, Steven A L W ^a,b   Troost, Freddy J ^a,b   Rijkers, Ger ^c   de Bruïne, Adriaan ^b   Bast, Aalt ^b   Venema, Koen ^a,d   Brummer, Robert Jan M ^a,b,e  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d TNO   (Netherlands)

^e ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Butyrate; Colonic inflammation; Cytokines; Glutathione; Oxidative stress; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUTYRIC ACID; C REACTIVE PROTEIN; CALGRANULIN; ENEMA; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 12; MESALAZINE; MYELOPEROXIDASE; PLACEBO; SODIUM CHLORIDE; SULFALAZINE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON MUCOSA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PATIENT COMPLIANCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; ANTIOXIDANTS; BIOPSY; BUTYRATES; COLITIS, ULCERATIVE; COLON; DOUBLE-BLIND METHOD; ENEMA; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; MUCOUS MEMBRANE; OXIDATIVE STRESS;

EID: 77955472405     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.04.002     Document Type: Article

References (51)

1. Ajani U.A., Ford E.S., Mokdad A.H. Dietary fiber and C-reactive protein: findings from national health and nutrition examination survey data. J Nutr 2004, 134:1181-1185.
2. Bingham S.A., Day N.E., Luben R., Ferrari P., Slimani N., Norat T., et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003, 361:1496-1501.
3. Poullis A., Foster R., Shetty A., Fagerhol M.K., Mendall M.A. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004, 13:279-284.
4. Streppel M.T., Ocke M.C., Boshuizen H.C., Kok F.J., Kromhout D. Dietary fiber intake in relation to coronary heart disease and all-cause mortality over 40 y: the Zutphen Study. Am J Clin Nutr 2008, 88:1119-1125.
5. Hamer H.M., Jonkers D., Venema K., Vanhoutvin S., Troost F.J., Brummer R.J. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008, 27:104-119.
6. Roediger W.E. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982, 83:424-429.
7. Vanhoutvin S.A., Troost F.J., Hamer H.M., Lindsey P.J., Koek G.H., Jonkers D.M., et al. Butyrate-induced transcriptional changes in human colonic mucosa. PLoS One 2009, 4:e6759.
8. Segain J.P., Raingeard de la Bletiere D., Bourreille A., Leray V., Gervois N., Rosales C., et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000, 47:397-403.
9. Miller S.J., Zaloga G.P., Hoggatt A.M., Labarrere C., Faulk W.P. Short-chain fatty acids modulate gene expression for vascular endothelial cell adhesion molecules. Nutrition 2005, 21:740-748.
10. Hamer H.M., Jonkers D.M.A.E., Bast A., Vanhoutvin S.A.L.W., Fischer M.A.J.G., Kodde A., et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009, 28:88-93.
11. Rosignoli P., Fabiani R., De Bartolomeo A., Spinozzi F., Agea E., Pelli M.A., et al. Protective activity of butyrate on hydrogen peroxide-induced DNA damage in isolated human colonocytes and HT29 tumour cells. Carcinogenesis 2001, 22:1675-1680.
12. Rodriguez-Cabezas M.E., Galvez J., Lorente M.D., Concha A., Camuesco D., Azzouz S., et al. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr 2002, 132:3263-3271.
13. Grisham M.B. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994, 344:859-861.
14. Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol 2005, 11:2371-2384.
15. Scheppach W., Sommer H., Kirchner T., Paganelli G.M., Bartram P., Christl S., et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992, 103:51-56.
16. Vernia P., Marcheggiano A., Caprilli R., Frieri G., Corrao G., Valpiani D., et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995, 9:309-313.
17. Holmes E.W., Yong S.L., Eiznhamer D., Keshavarzian A. Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig Dis Sci 1998, 43:1088-1095.
18. Welcker K., Martin A., Kolle P., Siebeck M., Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004, 9:456-460.
19. Xiang J.Y., Ouyang Q., Li G.D., Xiao N.P. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008, 14:53-57.
20. Fernandez-Banares F., Hinojosa J., Sanchez-Lombrana J.L., Navarro E., Martinez-Salmeron J.F., Garcia-Puges A., et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999, 94:427-433.
21. Hanai H., Kanauchi O., Mitsuyama K., Andoh A., Takeuchi K., Takayuki I., et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004, 13:643-647.
22. Russel M.G., Dorant E., Volovics A., Brummer R.J., Pop P., Muris J.W., et al. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum 1998, 41:33-40.
23. van der Heide H., van den Brandt-Gradel V., Tytgat G.N., Endert E., Wiltink E.H., Schipper M.E., et al. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988, 10:169-172.
24. O'Donnell L.J., Virjee J., Heaton K.W. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990, 300:439-440.
25. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
26. Saverymuttu S.H., Camilleri M., Rees H., Lavender J.P., Hodgson H.J., Chadwick V.S. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986, 90:1121-1128.
27. de Jager W., te Velthuis H., Prakken B.J., Kuis W., Rijkers G.T. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003, 10:133-139.
28. Vandeputte C., Guizon I., Genestie-Denis I., Vannier B., Lorenzon G. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol. Cell Biol Toxicol 1994, 10:415-421.
29. van der Sluijs Veer G., van den Hoven B., Russel M.G., van den Bergh F.A. Time-resolved fluorimetric immunoassay of calprotectin: technical and clinical aspects in diagnosis of inflammatory bowel diseases. Clin Chem Lab Med 2006, 44:292-298.
30. Vernia P., Annese V., Bresci G., d'Albasio G., D'Inca R., Giaccari S., et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003, 33:244-248.
31. Saemann M.D., Bohmig G.A., Osterreicher C.H., Burtscher H., Parolini O., Diakos C., et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. Faseb J 2000, 14:2380-2382.
32. Fusunyan R.D., Quinn J.J., Ohno Y., MacDermott R.P., Sanderson I.R. Butyrate enhances interleukin (IL)-8 secretion by intestinal epithelial cells in response to IL-1beta and lipopolysaccharide. Pediatr Res 1998, 43:84-90.
33. Gibson P., Rosella O. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. Gut 1995, 37:536-543.
34. Malago J.J., Koninkx J.F., Tooten P.C., van Liere E.A., van Dijk J.E. Anti-inflammatory properties of heat shock protein 70 and butyrate on Salmonella-induced interleukin-8 secretion in enterocyte-like Caco-2 cells. Clin Exp Immunol 2005, 141:62-71.
35. Weng M., Walker W.A., Sanderson I.R. Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia. Pediatr Res 2007, 62.
36. Nelson P.J., Ortiz B.D., Pattison J.M., Krensky A.M. Identification of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J Immunol 1996, 157:1139-1148.
37. Sanderson I.R. Dietary modulation of GALT. J Nutr 2007, 137:2557S-2562S.
38. Luhrs H., Gerke T., Muller J.G., Melcher R., Schauber J., Boxberge F., et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002, 37:458-466.
39. Senagore A.J., MacKeigan J.M., Scheider M., Ebrom J.S. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992, 35:923-927.
40. Steinhart A.H., Hiruki T., Brzezinski A., Baker J.P. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996, 10:729-736.
41. Breuer R.I., Soergel K.H., Lashner B.A., Christ M.L., Hanauer S.B., Vanagunas A., et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997, 40:485-491.
42. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996, 41:2254-2259.
43. Scheppach W., Muller J.G., Boxberger F., Dusel G., Richter F., Bartram H.P., et al. Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol 1997, 9:163-168.
44. Martensson J., Jain A., Meister A. Glutathione is required for intestinal function. Proc Natl Acad Sci U S A 1990, 87:1715-1719.
45. Aw T.Y. Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. Toxicol Appl Pharmacol 2005, 204:320-328.
46. Loguercio C., D'Argenio G., Delle Cave M., Cosenza V., Della Valle N., Mazzacca G., et al. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis 2003, 35:635-641.
47. Nieto N., Torres M.I., Fernandez M.I., Giron M.D., Rios A., Suarez M.D., et al. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Dig Dis Sci 2000, 45:1820-1827.
48. Den Hond E., Hiele M., Evenepoel P., Peeters M., Ghoos Y., Rutgeerts P. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology 1998, 115:584-590.
49. Santhanam S., Venkatraman A., Ramakrishna B.S. Impairment of mitochondrial acetoacetyl CoA thiolase activity in the colonic mucosa of patients with ulcerative colitis. Gut 2007, 56:1543-1549.
50. Pitcher M.C., Beatty E.R., Cummings J.H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000, 46:64-72.
51. Thibault R., De Coppet P., Daly K., Bourreille A., Cuff M., Bonnet C., et al. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology 2007, 133:1916-1927.